Anavex Life Sciences Corp. (AVXL) Stock Price Down 6.2%
Anavex Life Sciences Corp. (NASDAQ:AVXL)’s share price fell 6.2% during mid-day trading on Monday . The company traded as low as $3.39 and last traded at $3.47, with a volume of 1,061,401 shares traded. The stock had previously closed at $3.70.
A number of research firms have issued reports on AVXL. Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a report on Tuesday, May 31st. Maxim Group restated a “buy” rating and set a $15.00 price target on shares of Anavex Life Sciences Corp. in a report on Wednesday, May 11th. Finally, FBR & Co restated a “buy” rating on shares of Anavex Life Sciences Corp. in a report on Wednesday, June 22nd.
The stock’s market cap is $126.41 million. The stock has a 50-day moving average price of $5.39 and a 200 day moving average price of $4.84.
Anavex Life Sciences Corp. (NASDAQ:AVXL) last released its earnings results on Thursday, August 11th. The company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.03. On average, equities analysts predict that Anavex Life Sciences Corp. will post ($0.34) earnings per share for the current year.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.